Zosano Pharma Corporation (NASDAQ: ZSAN) announced the publication of Phase 1 trial data of influenza vaccine in the Journal of Vaccines and Immunology.

• The data demonstrated that a low dose of a trivalent influenza vaccine administered via its transdermal microneedle system produced antibody levels and was generally well tolerated.

• The Company noted that a lower dose of an influenza vaccine produced antibody levels similar to an intramuscular injection of the same vaccine at a higher dose.

• The single-center, randomized Phase 1 study enrolled 90 subjects between 18 to 40 years to receive a trivalent influenza vaccine containing strains A/H1N1, A/H3N2, and B.

• In November, the Company announced the successful formulation of a COVID-19 vaccine candidate utilizing its microneedle patch system.

• Zosano's patch consists of an array of approximately two thousand drug-coated titanium microneedles mounted on an adhesive patch that is administered to the skin using a reusable applicator.

• Price Action: ZSAN shares are up 11.8% at $0.58 during the market session on the last check Wednesday.

See more from Benzinga

• See Why Lixte Biotech Shares Trading At Over 100%?

• Edgewise Therapeutics Shares Jump After Positive Data On Becker Muscular Dystrophy Study

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.